Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Authors
Keywords
-
Journal
Artificial Cells Nanomedicine and Biotechnology
Volume 47, Issue 1, Pages 83-89
Publisher
Informa UK Limited
Online
2019-01-19
DOI
10.1080/21691401.2018.1543195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Systemic Therapy for Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma
- (2016) Hsin-An Chen et al. HEPATOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
- (2014) A. Furlan et al. CANCER RESEARCH
- Resistance to targeted cancer drugs through hepatocyte growth factor signaling
- (2014) Guus JJE Heynen et al. CELL CYCLE
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein
- (2014) Qing-feng Xiang et al. LIVER INTERNATIONAL
- Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
- (2014) B. Zhai et al. MOLECULAR CANCER THERAPEUTICS
- Met as a therapeutic target in HCC: Facts and hopes
- (2013) Silvia Giordano et al. JOURNAL OF HEPATOLOGY
- The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
- (2013) Ariel Ka-Man Chow et al. PLoS One
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells
- (2012) J-C Cheng et al. ONCOGENE
- Heparin Inhibits Hepatocyte Growth Factor Induced Motility and Invasion of Hepatocellular Carcinoma Cells through Early Growth Response Protein 1
- (2012) Evin Ozen et al. PLoS One
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway
- (2010) Po-Lin Kuo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression
- (2008) Sara Cabodi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now